News AZ, Organon fall foul of UK's code on pharma promotion AstraZeneca and Organon have breached the UK pharma industry's code of practice with promotions for an asthma drug and a contraceptive implant.
News Trials set up filings for AZ's triple therapy in asthma AstraZeneca's three-drug inhaler Breztri has shown efficacy for uncontrolled asthma in a pair of trials that could extend its label beyond COPD.
News Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
News Stopwatch starts on reviews of GSK's long-acting asthma drug Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.
News Study finds AZ's benralizumab a 'game-changer' in asthma Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if it was used to treat acute asthma attacks
News AZ, Avillion's Airsupra aces asthma rescue therapy trial A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.